D. Rominger

发表

A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine

Guodong Liu, Catherine Yuan, J. Violin, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Biased mu‐opioid receptor ligands: a promising new generation of pain therapeutics

J. Violin, D. Rominger, E. Siuda, 2017, Current opinion in pharmacology.

Biased ligands: pathway validation for novel GPCR therapeutics.

J. Violin, D. Rominger, C. Cowan, 2014, Current opinion in pharmacology.

Evidence for Allosteric Interactions of Antagonist Binding to the Smoothened Receptor

W. Zuercher, L. Mcmillan, R. Copeland, 2009, Journal of Pharmacology and Experimental Therapeutics.

Characterization of [125I]sauvagine binding to CRH2 receptors: membrane homogenate and autoradiographic studies.

B. Largent, D. Rominger, R. Grzanna, 1998, The Journal of pharmacology and experimental therapeutics.

Pharmacological Characterization of a Novel Nonpeptide Antagonist Radioligand, (±)-N-[2-Methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for Corticotropin-Releasing Factor1 Receptors

D. Rominger, C. Rominger, Xiao-Xin Yan, 2003, Journal of Pharmacology and Experimental Therapeutics.

. 5 ] decan-9-yl ] ethyl } ) amine ( TRV 130 ) , for the Treatment of Acute Severe Pain

J. Violin, S. Dewire, D. Yamashita, 2013 .

Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine.

R. Earl, D. Rominger, M. Pierdomenico, 1998, The Journal of pharmacology and experimental therapeutics.

Pharmacokinetics and Brain Penetration of Casopitant, a Potent and Selective Neurokinin-1 Receptor Antagonist, in the Ferret

C. Davis, D. Rominger, A. Shu, 2008, Drug Metabolism and Disposition.

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors

Ming-Chih Crouthamel, D. Rominger, P. Tummino, 2009, British Journal of Cancer.

Divergent Transducer-specific Molecular Efficacies Generate Biased Agonism at a G Protein-coupled Receptor (GPCR)*

Ryan T. Strachan, J. Violin, R. Lefkowitz, 2014, The Journal of Biological Chemistry.

Human Plasma In‐Cell Western Assays—An In vitro Predictor for In vivo Pharmacology in Oncology Drug Discovery

P. Scherle, D. Rominger, K. Vaddi, 2021, Current protocols.

Selectively Engaging β-Arrestins at the Angiotensin II Type 1 Receptor Reduces Blood Pressure and Increases Cardiac Performance

Lisa Nguyen, J. Violin, L. Nguyen, 2010, Journal of Pharmacology and Experimental Therapeutics.

Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain.

J. Violin, S. Dewire, D. Yamashita, 2013, Journal of medicinal chemistry.

Quantifying Ligand Bias at Seven-Transmembrane Receptors

Sudarshan Rajagopal, J. Violin, R. Lefkowitz, 2011, Molecular Pharmacology.

TRV0109101, a G Protein-Biased Agonist of the µ-Opioid Receptor, Does Not Promote Opioid-Induced Mechanical Allodynia following Chronic Administration

J. Violin, D. Rominger, C. Cowan, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Novel receptor site involved in enhancement of stimulus-induced acetylcholine, dopamine, and serotonin release.

D. Rominger, S. Tam, V. Nickolson, 1991, Molecular pharmacology.

Presenilin-1 and -2 Are Molecular Targets for γ-Secretase Inhibitors*

Robert A. Copeland, David W. Robertson, Qian Wang, 2000, The Journal of Biological Chemistry.

Evidence for Allosteric Interactions of Antagonist Binding to the Smoothened Receptor

W. Zuercher, L. Mcmillan, R. Copeland, 2009, Journal of Pharmacology and Experimental Therapeutics.

Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain.

S. Dewire, D. Yamashita, D. Rominger, 2013, Journal of medicinal chemistry.

[3H]DuP 734 [1-(cyclopropylmethyl)-4-(2'-(4''-fluorophenyl)-2'- oxoethyl)-piperidine HBr]: a receptor binding profile of a high-affinity novel sigma receptor ligand in guinea pig brain.

E. D. De Souza, D. Rominger, S. Tam, 1992, The Journal of pharmacology and experimental therapeutics.

Pharmacological Characterization of a Novel Nonpeptide Antagonist Radioligand, ( (cid:1) ) -N -[2-Methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1 H -1,2,3-triazolo[4,5-c ]pyridin-4-amine ([ 3 H]SN003) for Corticotropin-Releasing Factor 1 Receptors

D. Rominger, Cynthia M. Rominger, R. Zaczek, 2003 .